Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

0.69

Mkt cap

4.6M

Volume

99K

High

0.72

P/E Ratio

-0.26

52-wk high

3.10

Low

0.66

Div yield

N/A

52-wk low

0.61

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been awarded a patent for combining its proprietary genetic diagnostic with its lead investigational product AD04, for the treatment of alcohol and opioid use disorders. The patent is seen as a significant milestone in the company's pursuit to provide more effective treatments. The company's shares are up 3.06% at $2.86.

Portfolio Pulse from Vandana Singh

October 19, 2023 | 2:00 pm

Adial Pharmaceuticals has announced that its allowed claims cover the detection of select genotypes for the use of AD04 in treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD) patients.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 2:00 pm

Adial Pharmaceuticals has been awarded a Notice of Allowance for a key patent that combines the use of the company's proprietary genetic diagnostic with AD04 to treat alcohol and drug dependence.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 1:59 pm

During Wednesday's pre-market session, several healthcare stocks saw significant movement. Galecto (GLTO), MSP Recovery (LIFW), Cardiff Oncology (CRDF), Intelligent Bio Solutions (INBS), Biohaven (BHVN), and Eledon Pharma (ELDN) all saw increases, with Galecto leading the gainers with a 31.3% increase. On the other hand, Know Labs (KNW), Minerva Surgical (UTRS), Femasys (FEMY), Tharimmune (THAR), DMK Pharmaceuticals (DMK), and Adial Pharmaceuticals (ADIL) all experienced decreases, with Know Labs leading the losers with a 36.5% decrease.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 1:06 pm

Several healthcare stocks experienced significant movement in Tuesday's after-market session. Galecto, Exagen, MSP Recovery, Brainstorm Cell, VYNE Therapeutics, and Freeline Therapeutics saw increases, while Minerva Surgical, Femasys, DMK Pharmaceuticals, Adial Pharmaceuticals, Tharimmune, and SeqLL experienced decreases.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 9:31 pm

Adial Pharmaceuticals has regained compliance with Nasdaq's listing requirements, thereby avoiding potential delisting.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 12:31 pm

Several stocks have seen significant movement in pre-market trading. Notably, Palo Alto Networks, Inc. (NASDAQ:PANW) shares rose by 12.3% following better-than-expected Q4 earnings and a strong billings outlook. Other gainers include China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC), Tian Ruixiang Holdings Ltd (NASDAQ:TIRX), and Adial Pharmaceuticals, Inc. (NASDAQ:ADIL). On the other hand, Super League Gaming, Inc. (NASDAQ:SLGG) and Napco Security Technologies, Inc. (NASDAQ:NSSC) shares fell significantly.

Portfolio Pulse from Lisa Levin

August 21, 2023 | 12:32 pm

Adial Pharmaceuticals (NASDAQ:ADIL) reported its Q2 2023 financial results, revealing a cash position of $1.2M, down from $4M at the end of 2022. The company received positive feedback from US and EU regulatory meetings and is planning to conduct two Phase 3 trials with AD04. The sale of Purnovate significantly reduced the company's cash burn rate. Adial also received an upfront payment of $450K from Adovate, LLC for the purchase of Purnovate's assets and business, with potential for up to $83M in total consideration.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 12:32 pm

Several healthcare stocks experienced significant movement in Friday's after-market session. Adial Pharmaceuticals, Aytu BioPharma, Timber Pharmaceuticals, Mainz Biomed, Processa Pharma, and AIM ImmunoTech saw gains, while Assure Hldgs, T2 Biosystems, Biote, OpGen, Biophytis, and NeuroBo Pharmaceuticals experienced losses. Q2 earnings reports were recently released for several of these companies.

Portfolio Pulse from Benzinga Insights

August 18, 2023 | 9:32 pm

On Wednesday, 155 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was Estee Lauder Cos (NYSE:EL). The smallest company by market cap to set a new 52-week low was SenesTech (NASDAQ:SNES). Siyata Mobile (NASDAQ:SYTA)'s stock fell the most, as it traded down 7658.62% to reach a new 52-week low. Sutro Biopharma (NASDAQ:STRO) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 4:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.